A comprehensive analysis published in JAMA Internal Medicine confirmed these findings in real-world clinical settings, showing that tirzepatide consistently outperformed semaglutide for weight loss across different patient populations
A PCAC recommendation is not a rule, and a category change would not constitute FDA approval or create blend-level efficacy data
Regular monitoring helps identify these complications early
Tirzepatide may be appropriate for some patients with high blood pressure, but it depends on the full medical picture
Available from: Mullur N, Morissette A, Morrow NM, Mulvihill EE
From your initial comprehensive health consultation to ongoing monitoring and dosage adjustments, they ensure your safety and long-term success